Geode Capital Management LLC Buys 4,170 Shares of ClearPoint Neuro, Inc. (NASDAQ:CLPT)

Geode Capital Management LLC lifted its holdings in shares of ClearPoint Neuro, Inc. (NASDAQ:CLPT) by 1.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 287,294 shares of the company’s stock after buying an additional 4,170 shares during the period. Geode Capital Management LLC owned approximately 1.04% of ClearPoint Neuro worth $3,222,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Point72 DIFC Ltd purchased a new stake in shares of ClearPoint Neuro during the 2nd quarter valued at about $32,000. Barclays PLC lifted its holdings in shares of ClearPoint Neuro by 24.3% in the third quarter. Barclays PLC now owns 5,674 shares of the company’s stock worth $64,000 after buying an additional 1,109 shares in the last quarter. XTX Topco Ltd boosted its holdings in shares of ClearPoint Neuro by 11.6% during the 2nd quarter. XTX Topco Ltd now owns 13,010 shares of the company’s stock valued at $70,000 after purchasing an additional 1,353 shares during the last quarter. Verition Fund Management LLC purchased a new position in ClearPoint Neuro during the 3rd quarter valued at approximately $123,000. Finally, Oppenheimer & Co. Inc. bought a new stake in ClearPoint Neuro in the 3rd quarter worth approximately $156,000. 30.08% of the stock is owned by hedge funds and other institutional investors.

ClearPoint Neuro Stock Down 0.9 %

ClearPoint Neuro stock opened at $15.75 on Tuesday. ClearPoint Neuro, Inc. has a 52-week low of $5.11 and a 52-week high of $17.47. The firm’s fifty day moving average is $13.57 and its 200 day moving average is $11.15. The company has a market cap of $434.46 million, a price-to-earnings ratio of -22.83 and a beta of 1.01.

About ClearPoint Neuro

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.